Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways
Psaila B. et al, (2016), Genome Biology
Single cell RNA sequencing reveals molecular and functional platelet bias of aged hematopoietic stem cells
Nerlov C. et al, (2016), Nature Communications
A dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors
Buono M. et al, (2016), Nature Cell Biology
Ezh2 and Runx1 Mutations Targeted to Early Lymphoid Progenitors Collaborate to Promote Early Thymic Progenitor Leukemia
Booth C. et al, (2015), BLOOD, 126
Single Cell Whole Transcriptome Analysis Reveals Distinct Molecular Signatures of Therapy-Resistant Chronic Myeloid Leukemia Stem Cells
Giustacchini A. et al, (2015), BLOOD, 126
Application of single-cell genomics in cancer: promise and challenges.
Wills QF. and Mead AJ., (2015), Hum Mol Genet, 24, R74 - R84
Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB. and Mead AJ., (2015), Ther Adv Hematol, 6, 186 - 201
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Mead AJ. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 170, 29 - 39
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ. et al, (2015), Br J Haematol, 170, 29 - 39
PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
Mesa R. et al, (2015), HAEMATOLOGICA, 100, 336 - 337
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
Harrison C. et al, (2015), HAEMATOLOGICA, 100, 103 - 103
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
Psaila B. et al, (2015), HAEMATOLOGICA, 100, 97 - 97
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W. et al, (2015), Nat Commun, 6
Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial
Scherber R. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 81 - 81
Studying epigenomics in single cells: what is feasible and what can we learn?
Wills QF. et al, (2015), Epigenomics, 7, 1231 - 1234
Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML
Chowdhury O. et al, (2014), BLOOD, 124
Development and Evaluation of the Clinical Utility of a Next Generation Sequencing (NGS) Tool for Myeloid Disorders
Hamblin A. et al, (2014), BLOOD, 124
Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34-Human Acute Myeloid Leukemia
Quek L. et al, (2014), BLOOD, 124
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.
Harrison CN. et al, (2014), Br J Haematol, 167, 421 - 423